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The tradition of excellent summaries
established in the earlier 18 volumes of the
IARC series ofMonographs on the Evaluation
of the Carcinogenic Risk of Chemicals to
Humans has been maintained in the 19th.
The contents are extremely valuable to
toxicologists working in the plastics industry.
Attention has been directed to the plastics
that are used in huge amounts and to the
monomers from which they are polymerised,
so that one is not surprised to find mention of
vinyl chloride, polyethylene, polystyrene,
acrylates and nylon.
The assessment of carcinogenic potential of
the monomers follows the same lines as for
other chemicals, but the plastics present
special problems in their assessment, since all
of them produce local sarcoma when im-
planted s.c. in rats or mice. Unfortunately
there is no clear indication what importance
is given by the panel to the induction of
subcutaneous sarcoma by plastics as an index
of carcinogenic hazard to man. In the intro-
ductory section an attempt is made to assess
critically the experimental data thought to
be helpful towards this end. This attempt
starts very promisingly but ends weakly:
*on the basis of present information, it seems
possible that man-made polymeric materials
act by a combination ofphysical and chemical
careinogenesis: the design ofpast experiments
has not permitted definitive conclusions".
In fact there is a substantial number of
very well designed and well conducted past
experiments which show conclusively that,
whereas plastics in the form of a disc or
square 1-2 cm in size produce a high incidence
of sarcoma when implanted s.c. in rodents,
the same amount of material in powdered
form produces no tumours. This would argue
against chemical careinogenesis, since the
greatly increased surface area after shredding
would have led to an increase in tumour
incidence if the sarcomas had resulted from
a chemical interaction between the surface
of the solid and surrounding cells. Further-
more, discs imiade of materials like metallic
silver and gold, pure Jena glass and ivory
were just as efficient, as plastic discs in
producing sarcomas.
This adds up to one important fact: that
induction of subcutaneous sarcoma can result
from purely physical factors and is therefore
useless as an indication of carcinogenic
hazard; evidence for such hazard must be
sought by other means.
The assessment of negative results in
carcinogenicit,y tests is another unsatisfactory
area. When carcinogenicity tests are negative
the panel is at pains t,o find fault with the
test system: t,he numbers are inadequate, the
experiment w%as terminated too early, or
some detail of the experimental protocol wras
not published. Admittedly faults of this sort
lower the value of the experiment, but do not
make it valueless. Positive results from
experiments writh the same (or greater)
defect,s are seemingly accepted and pro-
nounced upon. The real truth is that negative
experimental data are no proof of absence of
carcinogenicity, but if the experiment is
reasonably conducted it gives some degree of
reassurance (wxithin the constraints of animal
experimentation) that any risk is likely to be
a small one. Not! all negative results can be
explained as experimental error.
On the positive side it is refreshing to note
that an objective view is being taken of
certain benign tumours in the mouse, the
induction of which has been the subject of
some controversv for several years.
In other respects the volume is a valuable
source of information for the harassed
toxicologist who often needs to have rapid
access t,o authoritative data. They are also
useful to the the cancer research worker in so
far as they provide a wealth ofdata on a wide
variety of chemicals which would otherwise
be hard to come by.
P. GRASSO
Potential Industrial Carcinogens and
Mutagens. L Fishbein (1979) Amsterdam:
Elsevier. 543 pp. $66-75.
The need for a handy reference manual to
guide industrial toxicologists, and othersBOOK REVIEWS 825
interested in this subject, through the maze
of information on industrial carcinogens and
mutagens is undisputed. The idea behind the
chapters and general layout of this volume is
good. The first 3 chapters introduce the
reader to the subject and outline some of the
problems posed by chemical interactions,
metabolism, risk assessment, epidemiology
and thresholds. The 4th chapter is a tabular
summary ofmutagenicity and carcinogenicity
data on 110 compounds. The remaining
chapters review information on production,
synthetic route, use and mutagenicity and
carcinogenicity data for 176 compounds. The
tabular summary and subsequent chapters
are arranged by chemical structure.
Unfortunately the excellent idea of a sum-
mary of this crucial information is not
carried through to the content. The first 3
introductory chapters appear to be a collage
of published views without any presentation
of the underlying hypotheses. The bases of
some of the major disagreements in the field
are not presented and, as a consequence, a
perplexing presentation of unsubstantiated
opinions results. The reader who does not
have a fairly extensive knowledge of this
subject will find this presentation confusing.
A second substantial criticism of this volume
is the extraordinary number oftypographical
and factual errors in every chapter. To check
all the facts presented is outside the scope of
the reviewer's task. The uninformed reader
is likely to be misled by these errors and even
the scientist working in the field is unable to
substantiate the tabular data in Chapter 4, as
there are no references. These errors are so
numerous that they will limit the usefulness
of the volume as a reference book.
I. F. H. PURCHASE
Immunotherapy of Human Cancer. (1978)
New York: Raven Press. 448 pp. $48-50.
The proceedings of a Symposium held at
the M. D. Anderson Hospital, this book
swells the ranks of recently published books
about human tumour immunotherapy. The
introduction by Drs Clark, Hickey and Hersh
contains the key to its understanding. At the
M. D. Anderson Hospital, we are told, there
are 20 immunotherapy trials in progress,
involving severalthousand patients. Immuno-
therapy is claimed to be the 4th major
modality of cancer treatment. Presumably
they believe that its value is as established as
the other 3. It works, they say, in acute
leukaemia, soft tissue and osteogenic sar-
comas, in malignant melanoma, gynaecologi-
cal and urogenital cancers, colorectal, breast
and lung tumours. Such an enthusiastic
introduction does not augur well for a rational
objective analysis of the topic.
The conference opens with a Heath
Memorial Award lecture by Professor Georges
Mathe, whose enthusiasm for immunotherapy
remains similarly unscathed. The rest of the
conference is logical, in form ifnot in content.
Four chapters examine the rational basis for
immunotherapy. Drs Fahey, Weiss and Fidler
present cautious but comprehensive essays,
examining in detail some mechanisms of host
resistance and how they might be mani-
pulated. The subsequent chapter on the
clinical reasons for trying immunotherapy,
by Dr Evan Hersh and 13 others, displays no
such caution and makes a variety of state-
ments that do not stand up to careful critical
examination. The main themes of their
argument are that (a) there is abundant
evidence for the immunogenicity of human
tumours and (b) that cancer patients are
immunodeficient. The evidence presented to
support these bold assertions, and therefore
the likely value of immunotherapy, is far
from convincing.
Starting the next section, on approaches
to immunotherapy, Dr David Weiss con-
tributes another valuable chapter about
animal models, the best thing in the book. It
is full of wit, erudition and objectivity. He
emphasizes the "distance between supposition
and reality" in transferring animal data to
human problems and roundly and rightly
condemns most of the animal model systems
in current use throughout the world.
The subsequent chapters describe the use of
exactly those models most devastatingly
criticised in Dr Weiss's essay. The use of
BCG and various extracted glycolipids,
Corynebacteria, thymosin, Levamisole, trans-
fer factor and isolated tumour "antigens" are
all in turn extolled. Dr Hollinshead's essay,
describing the latter, also tells us that high-
dose methotrexate works in lung cancer as a
form of immunotherapy because of rebound
overshoot! This is rather like banging your
head against a brick wall as a good treatment
for headache on the grounds that it feels good
once you stop.
The clinical chapters come next, in which